APT Medical AAQS
The The AAQS of APT Medical (688617.SS) as of Oct 21, 2026 is 6. In the previous year, The AAQS was 6.00 — a change of 0.00% (lower).
Get this data via API
Financial Data API
AAQS
6
YoY
0.00%
Last updated:
APT Medical has a current AAQS of 6.
A high AAQS can be seen as a positive indicator that the company is developing successfully.
Investors can assume that the company is on a good path to generate profits.
On the other hand, it is important to consider the AAQS of the stock APT Medical in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.
In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.
A high AAQS can be seen as a positive indicator that the company is developing successfully.
Investors can assume that the company is on a good path to generate profits.
On the other hand, it is important to consider the AAQS of the stock APT Medical in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.
In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.
The APT Medical AAQS history
3 Years
10 Years
25 Years
Max
AAQS
Date
AAQS
Jan 1, 2018
6.00 CNY
Jan 1, 2019
6.00 CNY
Jan 1, 2020
6.00 CNY
Jan 1, 2021
6.00 CNY
Jan 1, 2022
6.00 CNY
Jan 1, 2023
6.00 CNY
Jan 1, 2024
6.00 CNY
Jan 1, 2025
6.00 CNY
| YEAR | AAQS | YoY |
|---|---|---|
| 6 | 0.00% | |
| 6 | 0.00% | |
| 6 | 0.00% | |
| 6 | 0.00% | |
| 6 | 0.00% | |
| 6 | 0.00% | |
| 6 | 0.00% | |
| 6 | 0.00% | |
| 6 | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
APT Medical Stock analysis
What does APT Medical do? APT Medical Inc generates revenue through the research, development, production, and sale of electrophysiology, coronary access, and peripheral vascular intervention medical devices. The company offers electrophysiological electrode catheters, controllable radiofrequency ablation electrode catheters, and multichannel electrophysiological systems under its electrophysiology product line. Its coronary access segment includes guide wires, micro catheters, balloons, contrast guide wires, and catheters. Peripheral vascular intervention products address peripheral vascular diseases and are sold domestically and internationally. The firm also engages in original equipment manufacturer (OEM) business, producing products for other brands. Domestic and overseas markets are the primary sales channels for all product segments.
The company's electrophysiology products target healthcare providers specializing in cardiac procedures, while coronary access devices serve interventional cardiologists and vascular surgeons. Peripheral vascular intervention solutions are marketed to hospitals and clinics treating vascular conditions. OEM partnerships allow APT Medical to supply components to other medical device manufacturers without direct branding. These segments collectively drive revenue through direct sales to healthcare institutions and international distributors.
APT Medical Inc's product portfolio includes electrophysiological systems and coronary access tools that cater to specific medical specialties. The firm's peripheral vascular intervention products are designed for treating conditions like peripheral artery disease. OEM business contributes to revenue by manufacturing components for other companies' branded products. Domestic market sales and overseas distribution networks form the core of the company's commercial strategy, with no mention of specific customer names or financial figures beyond the employee count. APT Medical is one of the most popular companies on Eulerpool.
Frequently Asked Questions about APT Medical stock
The AAQS of APT Medical is 6 in 2025.
On Eulerpool you can find the complete historical development of The AAQS APT Medical since 2006 – with annual values, charts, and detailed analysis.
The AAQS is a key figure developed by AlleAktien.
The AAQS is a key figure developed by AlleAktien.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Quality — APT Medical
All Key Metrics — APT Medical
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth